Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 153 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Enoxaparine Clear all
Completed Phase 2 Interventional Results available

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

NCT01662908
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis
Interventions
edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Dothan, Alabama • Montgomery, Alabama • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 2, 2026, 6:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT

NCT04504318
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban 2.5 MG Oral Tablet, Enoxaparin 40Mg/0.4mL Prefilled Syringe
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 2, 2026, 6:29 AM EDT
Not listed Phase 4 Interventional

Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

NCT04169269
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters, Rivaroxaban 10 milligram Oral Tablet
Drug
Lead sponsor
Florida Orthopaedic Institute
Network
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 2, 2026, 6:29 AM EDT
Terminated Phase 4 Interventional Results available

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

NCT03296033
View directory record Official record
Conditions
Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
Interventions
Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 2, 2026, 6:29 AM EDT
Not yet recruiting Phase 3 Interventional

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

NCT06628778
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Enoxaparin
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2035
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 2, 2026, 6:29 AM EDT
Completed Phase 4 Interventional Results available

Enoxaparin Dosing in Obesity

NCT01798550
View directory record Official record
Conditions
Obesity
Interventions
Enoxaparin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 2, 2026, 6:29 AM EDT
Completed Phase 2 Interventional

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

NCT00402467
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban, (BAY59-7939), Enoxaparine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 2, 2026, 6:29 AM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 2, 2026, 6:29 AM EDT
Completed No phase listed Observational

Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients

NCT01727427
View directory record Official record
Conditions
Unsuspected Pulmonary Embolism
Interventions
Heparin, fondaparinux, vitamin-K antagonists, aspirin
Drug
Lead sponsor
G. d'Annunzio University
Other
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 2, 2026, 6:29 AM EDT
Completed No phase listed Observational

Heparin Induced Thrombocytopenia: Pharmacoeconomics

NCT00456001
View directory record Official record
Conditions
Heparin Induced Thrombocytopenia (HIT)
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Oct 2, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Results available

Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)

NCT01014403
View directory record Official record
Conditions
Venous Thromboembolism, Traumatic Brain Injury
Interventions
enoxaparin, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Dallas, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 2, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

NCT03251963
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Surgery
Interventions
Fixed Dose Enoxaparin, Variable Dose Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 2, 2026, 6:29 AM EDT
Completed No phase listed Observational

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

NCT04979780
View directory record Official record
Conditions
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,708 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Multiple Locations, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 2, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

NCT02271113
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GMI-1271, Placebo, Enoxaparin Sodium (Lovenox®)
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 2, 2026, 6:29 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)

NCT04861103
View directory record Official record
Conditions
Pregnancy, High Risk, Anticoagulants
Interventions
Lovenox
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 2, 2026, 6:29 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients

NCT02412982
View directory record Official record
Conditions
Traumatic Injury, Venous Thromboembolism
Interventions
Enoxaparin 40 mg q12h, Enoxaparin 30 mg q8h
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 2, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03891524
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 2, 2026, 6:29 AM EDT
Terminated Phase 3 Interventional

Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism

NCT01164046
View directory record Official record
Conditions
Venous Thromboembolism, Neoplasms
Interventions
low molecular weight heparin, vitamin K antagonists
Drug
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 2, 2026, 6:29 AM EDT
Not listed Phase 3 Interventional

Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose

NCT02486666
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 2, 2026, 6:29 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

NCT00426127
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Docetaxel, Liposomal Doxorubicin, Enoxaparin
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 2, 2026, 6:29 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19

NCT04377997
View directory record Official record
Conditions
Cardiovascular Diseases, COVID-19
Interventions
Enoxaparin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 2, 2026, 6:29 AM EDT
Withdrawn Phase 2 Interventional

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

NCT00916669
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Etoposide, Cisplatin, enoxaparin sodium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
4
States / cities
Boston, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2013 · Synced Oct 2, 2026, 6:29 AM EDT
Completed No phase listed Observational

Evaluation of Maternal and Fetal Outcomes in Pregnancies in Women With Prosthetic Heart Valves

NCT00329290
View directory record Official record
Conditions
Pregnancy, Anticoagulation, Prosthetic Heart Valves
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 2, 2026, 6:29 AM EDT
Completed Not applicable Interventional Results available

Strategies for Anticoagulation During Venovenous ECMO

NCT04997265
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism
Interventions
Low intensity anticoagulation, Moderate Intensity Anticoagulation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 2, 2026, 6:29 AM EDT